Category Blog

Medically Reviewed by: Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center Fact-Checked by: Generic Oncology Editorial Team Reviewed: July 2026 Hearing a new drug name for the first time is disorienting, especially when it comes wrapped up in…

Osimertinib, widely known by its brand name Tagrisso, represents a major advancement in oncology. It is a highly specialized pill. Doctors prescribe it for specific types of non-small cell lung cancer. Specifically, it targets tumors with certain genetic mutations. These…

IBRUTINIB PATIENT EDUCATION   |   Last reviewed: June 2026   |   Medical reviewer: [Salma Mamdouh Elreedy] Ibrutinib (brand name: Imbruvica) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s…

Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, Jobevne — and What “Biosimilar” Actually Means Patient and Caregiver Reference | Reviewed against FDA approval records and published comparative clinical trial data Last updated: June 2026 | Next scheduled review: June 2027 or upon…

A diagnosis of MASH (metabolic dysfunction-associated steatohepatitis) brings enough stress on its own. High out-of-pocket healthcare costs should not add to that burden. The FDA approved the brand-name drug Rezdiffra (Resmetirom 80 mg) in March 2024. Today, it retails for…